Advanced NanoTherapies, Inc developed breakthrough SirPlux Duo Drug-Coated Balloon for the treatment of small vessel coronary Arteries. It is applicable for coronary artery disease in vessels less than 3.0mm.
Small vessel disease (SVD), known as atherosclerosis within small (<3mm) coronary vessels, is noticed among 1 in 3 of patients. Its symptoms include coronary artery disease (CAD), especially in patients with chronic kidney disease (CKD), diabetes mellitus, and active smokers.
The tretament of small coronary vessels has become a challenge due to the unacceptable incidence of restenosis and target lesion failure inspite of having advances in drug-eluting stents.
The clinical profile of SVD patients translates into poor long-term outcomes, resulting in a higher rate of target lesion failure while using drug-eluting stents (DES).
The DCB becomes an attractive therapeutic strategy consisting of potential advantages such as lower risk of acute thrombosis, favorable vascular remodeling, and shortened dual antiplatelet therapy. Moreover, it also delivers low-dose, long-term release of both compounds inhibiting cell growth.
U.S. Food and Drug Administration (FDA) grants Breakthrough Device designation for SirPlux Duo Drug-Coated Balloon (DCB) for the treatment of small vessel coronary arteries.
